Laura R Marks1, Stephen Y Liang1,2, Dharushana Muthulingam1, Evan S Schwarz2,3, David B Liss2,3, Satish Munigala1, David K Warren1, Michael J Durkin1. 1. Division of Infectious Diseases, Washington University in St Louis School of Medicine, St Louis, Missouri, USA. 2. Division of Emergency Medicine, Washington University in St Louis School of Medicine, St Louis, Missouri, USA. 3. Section of Medical Toxicology, Washington University in St Louis School of Medicine, St Louis, Missouri, USA.
Abstract
BACKGROUND: Persons who inject drugs (PWID) are at risk of invasive infections; however, hospitalizations to treat these infections are frequently complicated by against medical advice (AMA) discharges. This study compared outcomes among PWID who (1) completed a full course of inpatient intravenous (IV) antibiotics, (2) received a partial course of IV antibiotics but were not prescribed any antibiotics on AMA discharge, and (3) received a partial course of IV antibiotics and were prescribed oral antibiotics on AMA discharge. METHODS: A retrospective, cohort study of PWID aged ≥18 years admitted to a tertiary referral center between 01/2016 and 07/2019, who received an infectious diseases consultation for an invasive bacterial or fungal infection. RESULTS: 293 PWID were included in the study. 90-day all-cause readmission rates were highest among PWID who did not receive oral antibiotic therapy on AMA discharge (n = 46, 68.7%), compared with inpatient IV (n = 43, 31.5%) and partial oral (n = 27, 32.5%) antibiotics. In a multivariate analysis, 90-day readmission risk was higher among PWID who did not receive oral antibiotic therapy on AMA discharge (adjusted hazard ratio [aHR], 2.32; 95% confidence interval [CI], 1.41-3.82) and not different among PWID prescribed oral antibiotic therapy on AMA discharge (aHR, .99; 95% CI, .62-1.62). Surgical source control (aHR, .57; 95% CI, .37-.87) and addiction medicine consultation (aHR, .57; 95% CI, .38-.86) were both associated with reduced readmissions. CONCLUSIONS: Our single-center study suggests access to oral antibiotic therapy for PWID who cannot complete prolonged inpatient IV antibiotic courses is beneficial.
BACKGROUND:Persons who inject drugs (PWID) are at risk of invasive infections; however, hospitalizations to treat these infections are frequently complicated by against medical advice (AMA) discharges. This study compared outcomes among PWID who (1) completed a full course of inpatient intravenous (IV) antibiotics, (2) received a partial course of IV antibiotics but were not prescribed any antibiotics on AMA discharge, and (3) received a partial course of IV antibiotics and were prescribed oral antibiotics on AMA discharge. METHODS: A retrospective, cohort study of PWID aged ≥18 years admitted to a tertiary referral center between 01/2016 and 07/2019, who received an infectious diseases consultation for an invasive bacterial or fungal infection. RESULTS: 293 PWID were included in the study. 90-day all-cause readmission rates were highest among PWID who did not receive oral antibiotic therapy on AMA discharge (n = 46, 68.7%), compared with inpatient IV (n = 43, 31.5%) and partial oral (n = 27, 32.5%) antibiotics. In a multivariate analysis, 90-day readmission risk was higher among PWID who did not receive oral antibiotic therapy on AMA discharge (adjusted hazard ratio [aHR], 2.32; 95% confidence interval [CI], 1.41-3.82) and not different among PWID prescribed oral antibiotic therapy on AMA discharge (aHR, .99; 95% CI, .62-1.62). Surgical source control (aHR, .57; 95% CI, .37-.87) and addiction medicine consultation (aHR, .57; 95% CI, .38-.86) were both associated with reduced readmissions. CONCLUSIONS: Our single-center study suggests access to oral antibiotic therapy for PWID who cannot complete prolonged inpatient IV antibiotic courses is beneficial.
Authors: Yoelkys Morales; Emma Smyth; Julia Zubiago; Benjamin Bearnot; Alysse G Wurcel Journal: Open Forum Infect Dis Date: 2022-10-19 Impact factor: 4.423
Authors: Ayesha Appa; Meredith Adamo; Stephenie Le; Jennifer Davis; Lisa Winston; Sarah B Doernberg; Henry Chambers; Marlene Martin; Nancy K Hills; Phillip O Coffin; Vivek Jain Journal: Clin Infect Dis Date: 2022-01-29 Impact factor: 9.079
Authors: Nikhil Seval; Cynthia A Frank; Alain H Litwin; Prerana Roth; Meredith A Schade; Martina Pavlicova; Frances R Levin; Kathleen T Brady; Edward V Nunes; Sandra A Springer Journal: Contemp Clin Trials Date: 2021-04-07 Impact factor: 2.261
Authors: Joëlla W Adams; Alexandra Savinkina; James C Hudspeth; Mam Jarra Gai; Raagini Jawa; Laura R Marks; Benjamin P Linas; Alison Hill; Jason Flood; Simeon Kimmel; Joshua A Barocas Journal: JAMA Netw Open Date: 2022-02-01
Authors: David P Serota; Hansel E Tookes; Belén Hervera; Babley M Gayle; Cara R Roeck; Edward Suarez; David W Forrest; Michael A Kolber; Tyler S Bartholomew; Allan E Rodriguez; Susanne Doblecki-Lewis Journal: Ann Med Date: 2021-12 Impact factor: 5.348
Authors: Jorge Valencia; Jesús Troya; Jeffrey V Lazarus; Guillermo Cuevas; Alejandro Alvaro-Meca; Juan Torres; Carlos Gardeta; David Lozano; Santiago Moreno; Pablo Ryan Journal: Open Forum Infect Dis Date: 2021-05-25 Impact factor: 3.835